#USA #Austin #TROP2 #Genprex #Reqorsa

Genprex Reveals TROP2 Biomarker in Lung Cancer Gene Therapy

In an exciting advancement for cancer treatment, Genprex, Inc. has announced compelling research indicating that TROP2 may serve as a predictive biomarker for the efficacy of its innovative gene therapy, Reqorsa® (quaratusugene ozeplasmid). This research will be presented at the 2026 EORTC-NCI-AACR Symposium held in Barcelona, Spain from November 18-20, 2026.

The study reveals that patients exhibiting low levels of TROP2 expression could show primary resistance to Reqorsa in various preclinical models of non-small cell lung cancer (NSCLC). The findings, derived from both laboratory analysis and patient biopsies, highlight a significant correlation between TROP2 levels and therapeutic responsiveness. Ryan Confer, the President and CEO of Genprex, emphasized the importance of this discovery, noting that identifying a reliable biomarker could revolutionize patient selection and treatment strategy, ultimately leading to more personalized therapies for lung cancer sufferers.

Implications of TROP2 in Lung Cancer Treatments

This research underscores the role of TROP2, a tumor-associated protein, in determining the effectiveness of Reqorsa. Approximately 50% of the NSCLC cell lines studied and the organoid models derived from patients consistently exhibited resistance to gene delivery tied to low TROP2 expression. Further supporting evidence arose from the analysis of biopsies collected from clinical trial participants who were undergoing treatment with Reqorsa. These biopsies corroborated the connection between TROP2 expression levels and patient response to therapy.

The study implicates that manipulating TROP2 levels could enhance the effectiveness of Reqorsa, paving the way for more tailored therapeutic approaches. Genprex’s ongoing investigations aim to delve deeper into how changing TROP2 signaling can impact therapeutic outcomes, inviting the potential for improved survival rates and quality of life for lung cancer patients.

About Reqorsa® Gene Therapy

Reqorsa® is a cutting-edge gene therapy product that delivers the TUSC2 gene, a key player in tumor suppression, housed within lipid-based nanoparticles. This innovative formulation allows Reqorsa to selectively target and penetrate cancer cells without affecting normal tissues, showcasing a preferential uptake between 10 to 33 times higher in tumor cells compared to healthy cells. As Genprex continues to push the boundaries of gene therapy, it remains focused on not just advancing treatment options to combat NSCLC but also aims to provide new solutions for other challenging medical areas, including diabetes.

The company is currently running two pivotal clinical trials—Acclaim-1 and Acclaim-3—to evaluate the effectiveness of Reqorsa in patients diagnosed with non-small cell lung cancer and small cell lung cancer. With both studies having received Fast Track Designation from the U.S. FDA, Genprex aims to streamline the approval process for their promising therapies that could address significant unmet medical needs.

Future Perspectives

As the findings regarding TROP2's predictive capability gain traction, Genprex’s path forward looks promising. The company is committed to further research to validate these results and advance the understanding of biomarker-driven therapies. In a world where cancer treatments are increasingly personalized, TROP2 could become a cornerstone for improving treatment outcomes in lung cancer.

Genprex invites both patients and the scientific community to stay informed and engaged as they navigate this revolutionary phase in the battle against cancer. Stay tuned for the upcoming presentation at the EORTC-NCI-AACR Symposium, where the detailed findings will be unveiled, marking another significant milestone in the journey towards effective and personalized cancer treatment solutions.